Product Datasheet

Flibanserin


Catalog No. **BP-01920** · CAS **167933-07-5** · Form **free base** · Physical state **solid** · Color **white to off-white** · Version **1.0** · Revision **2026-11-09**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
5-HT Receptor; Dopamine Receptor	**Neurological Disease; Cancer**

Molecular formula	$C_{20}H_{21}F_3N_4O$
Molecular weight	**390.4021**

STRUCTURE



DESCRIPTION

Flibanserin (BIMT-17; BIMT-17BS) is an orally active serotonin 5-HT1A receptor agonist and 5-HT2A receptor antagonist with Ki values of 1 nM and 49 nM, respectively.

BIOLOGICAL ACTIVITY

Flibanserin (BIMT-17; BIMT-17BS) is an orally active serotonin 5-HT1A receptor agonist and 5-HT2A receptor antagonist with Ki values of 1 nM and 49 nM, respectively. Flibanserin binds to dopamine D4 receptors with an Ki value of 4-24 nM. Flibanserin shows anti-depression and anti-anxiety effect, can be used to hypoactive sexual desire disorder (HSDD) research.

SOLUBILITY

Soluble in DMSO

REFERENCES

[1]. Fayed M, et al. Insights into Flibanserin Oxidative Stress Degradation Pathway: In Silico – In Vitro Toxicity Assessment of Its Degradates[J]. New Journal of Chemistry, 2021.

[2]. Invernizzi RW, et al. A potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors. Br J Pharmacol. 2003 Aug;139(7):1281-8.

[3]. Podhorna J, et al. Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety. Br J Pharmacol. 2000 Jun;130(4):739-46.

[4]. Gelez H, et al. Brain neuronal activation induced by flibanserin treatment in female rats. Psychopharmacology (Berl). 2013 Dec;230(4):639-52.

[5]. Gelman F, et al. Flibanserin for hypoactive sexual desire disorder: place in therapy. Ther Adv Chronic Dis. 2017 Jan;8(1):16-25.